EMA Authorised: Kefdensis (denosumab) — Stada Arzneimittel AG

View source ↗

Summary

The EMA has authorised Kefdensis (denosumab) by Stada Arzneimittel AG for conditions related to bone resorption and osteoporosis, including postmenopausal osteo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Osteoporosis Postmenopausal

Drugs mentioned

• Kefdensis (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal. MAH: Stada Arzneimittel AG. Decision date: 17/07/2026